<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03158948</url>
  </required_header>
  <id_info>
    <org_study_id>MOT-C-201</org_study_id>
    <nct_id>NCT03158948</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of 3 Doses of MOTREM in Patients With Septic Shock</brief_title>
  <official_title>Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of 3 Doses of MOTREM in Patients With Septic Shock. A Randomised, Double-blind, Two-Stage, Placebo Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Inotrem</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Inotrem</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomised, double-blind, two-stage, placebo controlled study. It is designed to
      investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of 3 doses of
      MOTREM versus placebo in adult patients with septic shock.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 3, 2017</start_date>
  <completion_date type="Anticipated">August 2018</completion_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomised, Double-blind, Two-Stage, Placebo Controlled</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Vital signs</measure>
    <time_frame>28 days</time_frame>
    <description>systolic (SBP) and diastolic (DBP) blood pressure, heart rate, and body temperature (tympanic)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ECG</measure>
    <time_frame>28 days</time_frame>
    <description>12-lead ECG</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients with clinically relevant abnormal laboratory values</measure>
    <time_frame>28 days</time_frame>
    <description>Laboratory tests related to hematology, biochemistry and coagulation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Presence of anti-LR12 antibodies</measure>
    <time_frame>28 days</time_frame>
    <description>Number of patients with anti-LR12 anti drug antibodies</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse events</measure>
    <time_frame>28 days</time_frame>
    <description>Number of patients with adverse events</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Shock, Septic</condition>
  <arm_group>
    <arm_group_label>MOTREM 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.3 mg/kg/h</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MOTREM 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1.0 mg/kg/h</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MOTREM 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3.0 mg/kg/h</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MOTREM</intervention_name>
    <description>Formulated LR12 peptide</description>
    <arm_group_label>MOTREM 1</arm_group_label>
    <arm_group_label>MOTREM 2</arm_group_label>
    <arm_group_label>MOTREM 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provide written informed consent (proxy/legal representative) according to local
             regulations

          -  Age 18 to 80 years

          -  Documented or suspected infection: lung, abdominal or elderly UTI (≥65 years)

          -  Organ dysfunction defined as acute change in SOFA score ≥ 2 points

          -  Refractory hypotension requiring vasopressors to maintain MAP ≥65mm Hg despite
             adequate volume resuscitation of at least 20 ml/kg within 6 hours

          -  Hyperlactatemia (blood lactate &gt;2 mmol/L or 18 mg/dL). This criterion must be met at
             least once for the purpose of diagnosis within the 24 hours before study drug
             administration

        Exclusion Criteria: -

          -  Previous episode of septic shock (vasopressor administration) within current hospital
             stay

          -  Underlying concurrent immunodepression (specified in appendix 2)

          -  Solid organ transplant requiring immunosuppressive therapy

          -  Known pregnancy (positive serum pregnancy test)

          -  Prolonged QT syndrome (QTc ≥ 440 ms)

          -  Shock of any other cause, e.g. hypotension related to gastrointestinal bleeding

          -  Ongoing documented or suspected endocarditis, history of prosthetic heart valves

          -  End-stage neurological disease

          -  End-stage cirrhosis (Child Pugh Class C)

          -  Acute Physiology And Chronic Health Evaluation (APACHE) II score ≥ 34

          -  End stage chronic renal disease requiring chronic dialysis

          -  Home oxygen therapy on a regular basis for &gt; 6 h/day

          -  Severe obesity (BMI ≥ 40)

          -  Recent CPR (within current hospital stay)

          -  Moribund patients

          -  Decision to limit full care taken before obtaining informed consent

          -  Participation in another interventional study in the 3 months prior to randomisation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bruno François, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Inserm 1435 Clinical Investigational Center, Limoges, France</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cliniques Universitaires Saint-Luc (there may be other sites in this country)</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inserm Clinical Investigational Center, CHU Dupuytren (there may be other sites in this country)</name>
      <address>
        <city>Limoges Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radboudumc (there may be other sites in this country)</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico San Carlos, Medicina Intensiva (there may be other sites in this country)</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Netherlands</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 16, 2017</study_first_submitted>
  <study_first_submitted_qc>May 17, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 18, 2017</study_first_posted>
  <last_update_submitted>April 5, 2018</last_update_submitted>
  <last_update_submitted_qc>April 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sepsis</keyword>
  <keyword>LR12</keyword>
  <keyword>TREM1</keyword>
  <keyword>TREM-1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Shock</mesh_term>
    <mesh_term>Shock, Septic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

